Cellectis S.A.
$3.65+0.55%(+$0.02)
TickerSpark Score
51/100
65
Valuation
40
Profitability
55
Growth
64
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLLS research report →
52-Week Range56% of range
Low $1.33
Current $3.65
High $5.48
Companywww.cellectis.com
Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.
- CEO
- Andre Choulika
- IPO
- 2015
- Employees
- 216
- HQ
- Paris, FR
Price Chart
+137.01% · this period
Valuation
- Market Cap
- $366.48M
- P/E
- -5.62
- P/S
- 3.99
- P/B
- 6.31
- EV/EBITDA
- -7.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.86%
- Op Margin
- -69.23%
- Net Margin
- -98.69%
- ROE
- -80.61%
- ROIC
- -26.92%
Growth & Income
- Revenue
- $72.95M · 75.76%
- Net Income
- $-67,593,000 · -83.87%
- EPS
- $-0.68 · -65.85%
- Op Income
- $-33,076,000
- FCF YoY
- -317.70%
Performance & Tape
- 52W High
- $5.48
- 52W Low
- $1.33
- 50D MA
- $3.71
- 200D MA
- $3.76
- Beta
- 2.93
- Avg Volume
- 40.58K
Get TickerSpark's AI analysis on CLLS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Our CLLS Coverage
We haven't published any research on CLLS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLLS Report →Similar Companies
ANRO+0.68%
Alto Neuroscience, Inc.
$20.59
ACIU+2.30%
AC Immune S.A.
$2.88
ALDX-1.95%
Aldeyra Therapeutics, Inc.
$1.51
AMRN+1.07%
Amarin Corporation plc
$14.20
DRTS+3.75%
Alpha Tau Medical Ltd.
$11.08
LRMR+1.19%
Larimar Therapeutics, Inc.
$3.37
SLN+8.09%
Silence Therapeutics plc
$6.24
DBVT+0.30%
DBV Technologies S.A.
$18.56